The manufacturer claims the drug has a 100% prevention rate in women US biopharmaceutical company Gilead Sciences Inc. has claimed that an experimental vaccine has demonstrated 100% efficacy for the prevention of HIV infections in women, after conducting trials in South Africa and Uganda Trials with the twice-yearly ‘lenacapavir’ shot involved about 5,300 women aged between 16 and 25, the company announced last week. Some were injected with lenacapavir while others received the company’s older Truvada medication, which is taken orally once a day. “First Phase 3 HIV Prevention Trial Ever to Show Zero Infection
Hence then, the article about 42 000 a year hiv vaccine trialed in africa was published today ( ) and is available onRussia Today ( News ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( $42,000-a-year HIV vaccine trialed in Africa )